Predicting tumour progression is one of the major challenges in oncology. Scientists at the University of Geneva (UNIGE) and the Ludwig Institute for Cancer Research have discovered that neutrophils, a type of immune cell, undergo reprogramming when they come into contact with the tumour ecosystem and contribute to its progression. They then produce a molecule — the chemokine CCL3 — which promotes cancer growth rather than fighting it. This mechanism appears to be a major variable in tumour biology and could serve as an indicator of disease progression. These findings are published in the journal Cancer Cell.

BUFFALO, NY — February 5, 2026 — A new case report was published in Volume 12 of Oncoscience on December 23, 2025, titled “Silent toxicity: A rare case of 5-fluorouracil-induced hyperammonemic encephalopathy.”

BrainIAC is an innovative AI foundation model developed by Mass General Brigham that was trained on nearly 49,000 brain MRI scans to identify key neurological health indicators, such as brain age and dementia risk, without the need for extensive labeled datasets. In a new study, it outperformed traditional task-specific models, demonstrating effectiveness in various clinical applications.

Liver cancer is one of the three deadliest cancers worldwide, and metabolic dysfunction-related cases have become increasingly common in recent years. A research team from The Hong Kong Polytechnic University (PolyU) has identified a protein secreted by fat cells that promotes cancer growth and has successfully developed a novel antibody that neutralises this protein, marking a significant breakthrough in impeding the progression of liver cancer. The research findings have been published in the Journal of Clinical Investigation.

POSTECH and ImmunoBiome researchers uncover a novel microbiota-Tfh cell axis to enhance antibody production and mucosal vaccine efficiency.

Researchers from the HUN-REN Szeged Biological Research Centre and HCEMM have just published a new study suggesting that it’s not simply the number of tumour mutations that matters for immunotherapy, but the kind of mutation patterns they create. The team found a distinct “fingerprint” linked to DNA repair problems and chemical exposures that can leave tumours surprisingly hard for the immune system to spot, even when mutation counts are high. The study also points out that a patient’s genetics, including common HLA types in Europeans, can shift how visible the same tumour looks to T cells. The paper was published recently in Molecular Systems Biology.

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to treat multiple solid tumors. The study focused on engineered invariant natural killer T cells, or NKT cells — powerful immune cells with a unique ability to infiltrate solid tumors — and systematically compared four targeting systems, called chimeric antigen receptors, or CARs, that direct these cells to attack cancer.